November 22, 2024

The Catholic Transcript

Complete News World

NY stocks close higher in the US with epidemic news and indicators Jornal Midiamax

NY stocks close higher in the US with epidemic news and indicators Jornal Midiamax

This Wednesday, the 22nd, the New York Stock Exchange closed heavily, with signs of epidemiology in another session and indications of treatments isolated from the fear of the Omigron variant of the corona virus. In addition, the release of indicators in the United States stood out, showing both the results exceeding the expectations of analysts, including the correction of the country’s GDP and consumer confidence.

The Dow Jones industrial average was up 0.74% at 35753.89 points, the S&P 500 was up 1.02% at 4696.56 points and the Nasdaq was up 1.18% at 15521.89 points.

According to Onda’s researcher Edward Moya, measures have been stepped up by US and UK efforts to secure treatments for Kovit-19. In turn, trade volumes will continue to fall towards the holidays this weekend, and Omigron will fight risk appetite to deliver a significant stock market rally as it poses a greater risk to many health systems. Today, the US regulatory body, which is affiliated with Anvisa, approved the emergency use of Pfizer’s oral therapy against Kovit-19, and the company’s shares rose 1.02%.

According to Moya, it is not possible to return to the locks seen at the beginning of the epidemic in the United States, but American consumers will be vulnerable because many Americans will not have the same benefits if their jobs are temporarily shut down. Today, the local consumer confidence index rose from 111.9 in November to 115.8 in December, surpassing analysts’ forecasts of 110.0. Another data that surpassed forecasts was US GDP, which recorded a growth of 2.3% in the third quarter of 2021, higher than the previous reading of 2.1%.

See also  Israel sends strong warning to Hamas terrorists: "Patience is exhausted"

Following the release, Oxford Economics estimates that US economic growth will slow to 4% in 2022 from 5.7% in 2021. “Failure to comply with President Joe Biden’s built-back package puts us at risk of lowering our forecast for 2022,” the advice exemplifies. , Which also indicates the potential impact of Omigran in the coming year.

Among highlights, Tesla’s shares rose 7.49% on the same day that the company’s CEO Elon Musk announced that it had sold more shares and had now reached the 10% target for its participation offer.